CVS’s Zepbound Reversal Shows the Real Drug-Pricing Machine
Reuters reported that CVS Health pharmacy-benefit manager, Caremark, will add Eli Lilly obesity drug Zepbound back to its commercial formularies as a preferred coverage option starting October 1. Caremark had dropped Zepbound last July while keeping Novo Nordisk Wegovy after negotiating a better price, according to the report. CVS said the move was part of efforts to tackle affordability and access for GLP-1 weight-loss medicines. Reuters also reported that CVS is removing a new-to-market block on Lilly oral weight-loss pill, Foundayo, beginning June 1. The change comes as employers, insurers, drugmakers, and pharmacy-benefit managers continue fighting over the cost and coverage of highly demanded obesity drugs. The public-facing issue is not simply whether one drug beats another; it is how opaque formulary decisions determine who gets access and when.
The CVS reversal on Zepbound is not just a drug-coverage story. It is a window into the machinery Americans are forced to navigate when medicine, insurance, employer benefits, and financial engineering all meet in the same room.
Caremark dropped Zepbound from preferred coverage last year after negotiating better terms for Wegovy. Now Zepbound is coming back as a preferred option. The companies can describe that as normal formulary management, and technically it is. But for patients and employers, the practical lesson is harsher: access to a major medicine can change because the rebate math changed.
That is the part the public should focus on. The health system talks about clinical value, affordability, and access. But the actual operating system is a chain of negotiated discounts, preferred lists, blocks, exclusions, employer cost pressure, and pharmacy-benefit-manager incentives that ordinary people cannot see. A patient hears about a drug. A doctor may think it is appropriate. But the deciding layer is often an opaque contract between large institutions.
GLP-1 drugs make this impossible to ignore because demand is enormous and costs are high. Employers do not want benefit budgets blown up. Insurers do not want open-ended exposure. Drugmakers want market share. PBMs say they are using formulary leverage to obtain better prices. Each actor can claim a rational motive. The combined result is a system where the citizen experiences uncertainty, delay, and a constantly shifting rulebook.
This is a fiscal story as much as a health story. America spends more on healthcare than peer countries, yet the spending does not buy simplicity. It buys administrative layers. It buys middlemen. It buys paperwork. It buys negotiated opacity. And because employer-sponsored coverage is tied to wages and business costs, the bill shows up everywhere: lower take-home pay, higher premiums, narrower coverage, and more resentment toward institutions that appear to make life harder while claiming to manage cost.
There is also a trust problem. When a drug is excluded one year and restored the next, people reasonably ask whether the decision was about their health or someone else deal. That does not mean every formulary change is corrupt. It means the structure invites suspicion because the decisive information is hidden.
A healthier system would make the tradeoffs visible. If a PBM says it saved employers money, show how much. If a drug is excluded, explain the clinical and financial basis in language normal people can understand. If rebates drive access, admit it. Stop pretending the patient is at the center while the real battle happens in contracts the patient will never see.
The Zepbound reversal is a small event inside a giant system. But it captures the bigger problem: America has built a healthcare machine that is financially sophisticated and humanly exhausting. Until that changes, every coverage announcement will feel less like a public-health decision and more like another move in a pricing game citizens are required to fund but not allowed to inspect.